This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



EfficacyEfficacyKey Take AwaysHospitalisation DataSafetySafetyAdverse Event Management: VOD/SOSSelected Adverse ReactionsDosingDosing and Dose ModificationsAdministrationSupport and ResourcesPublications
Hospitalisation DataAim for Reduced Hospitalisation Burden1

In a retrospective analysis of data from the INO-VATE ALL study; of the patients who received at least one dose of study drug (BESPONSA n=164 vs SC n=143), BESPONSA reduced hospitalisation burdens when compared with standard chemotherapy.1

Hospitalisation for both groups was mainly for treatment of underlying disease and toxicity associated with R/R ALL treatment including haematologic toxicity and infection.1

IRR=incidence rate ratio; SC=standard chemotherapy.Lower Percentage of Treatment Time Spent in Hospital for BESPONSA vs SC1Overall, 136 of 164 (82.9%) BESPONSA patients and 135 of 143 (94.4%) SC patients experienced at least one hospitalisation.1
BESPONSA patients spent substantially longer on treatment vs SC patients: 85 days vs 45 days per patient (in total 13,946 days vs 6,463 days), respectively.1
*Treatment of underlying disease includes hospitalisations for scheduled treatment related to ALL or study participation, relapse and preparation for HSCT.ALL=acute lymphoblastic leukemia; HSCT=hematopoietic stem cell transplantation; SC=standard chemotherapy.
ALL=acute lymphoblastic leukemia; EMD=extramedullary disease; R/R=relapsed/refractory; SmPC=Summary of Product Characteristics.References:Marks DI, et al. Cancer Med. 2019;8(13):5959-5968.
Efficacy Safety Visit Loading
Besponsa Prescribing Information
Visit Loading

Legal Category: S1A
Further information is available upon request

PP-INO-IRL-0109 January 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024